BIOGRAPHICAL SKETCH 　 　

NAME: Y u , Li 　 　

POSITION TITLE: Distinguished Professor in department of Hematology and ?Oncology, Shenzhen University School of Medicine ; ?Distinguished professor of Nankai University and Tsinghua University; Director in Department of Hematology and Oncology, Shenzhen University General Hospital; ? Executive Director of Carson International Cancer Center. 　 　

TEL ： +86-13910037231; ??????????OFFICE PHONE: +86- 0755-21839215 ; ? ???????????E - MAIL: liyu301@vip.163.com 　 　

EDUCATION/TRAINING 　 　

?

?

INSTITUTION AND LOCATION	DEGREE 　 ?	? Completion Date MM/YYYY 　 　 　?	FIELD OF STUDY
Norman Bethune University of Medical Sciences, Chang-Chun, China	B. Med ?	06/1982	Medicine
Chinese PLA General Hospital, Postgraduate Medical School, Beijing, China	M.M.	06/1991	Hematology
Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China	Ph.D.	06/1994	Oncology
Comprehensive Cancer Center , Ohio State University, Columbus, Ohio, USA	Postdoctoral	1998	Hematology and ?Oncology
Comprehensive Cancer Center , Ohio State University, Columbus, Ohio, USA	Visiting Scholar	2004	Hematology and ?Oncology

　?　 　 　

A.? Personal Statement 　 　

My research interests fall in Transplantation immunology , ? Genetic and Epigenetic study on leukemia ? Mole- cular and Diagnosis of leukemia. ? I had served as the di rector in ?Department of ?Hematology and BMT Laboratory of Chinese PLA General Hospital, Beijing, China ?from ?20 06 ?to 2017.I manage an independent Hematology laboratory ?of approximately 120 m2 in area in Shenzhen University , ?School of Medicine . I have trained more than 20 PhD students and ?over 10 postdoctoral students. And ?I have take n ?more than 10 projects including the Major State Basic Research Development Program of China (973 Program), National High Technology Research and Development Program of China (863 Program), National Natural Science Foundation of China. At present, more than 7 million RMB ? has been funded by government ?in terms of my projects . ? I have published ?more than ? 120 SCI papers in leading international journals such as Nature Genetics, Blood and Leukemia et al. 　 　

　?　 　 　

B.? Positions and Employment 　 　

19 8 2-19 94 ????????Resident Doctor, Department of Hematology, Chinese PLA General Hospital, Postgraduate Medical School, Beijing, China 　 　

1994-1996 ????????Attending Doctor, Department of Hematology, Chinese PLA General Hospital, Postgraduate 　 　

Medical School, Beijing, China 　 　

1996-2000 ???????Associate Professor , ?Department of Hematology, Chinese PLA General Hospital, 　 　

Postgraduate Medical School, Beijing, China 　 　

2000-2006 ????????Professor, Department of Hematology, Chinese PLA General Hospital, Postgraduate Medical School, Beijing, China 　 　

2006-2017 ??????Director, Department of Hematology and BMT Center, Chinese PLA General ? Hospital, 　 　

Beijing, China 　 　

2017-present ?Director, Department of Hematology and Oncology, Shenzhen University General Hospital 　 　

? ????? 　 　

C.? Experience and Honors 　 　

1.? Inviting reviewer, Blood; 　 　

2.? Inviting reviewer, Oncogene; ? 　 　

3.? Inviting reviewer, Oncotarget; ? 　 　

4.? Inviting reviewer, Plos One; ? 　 　

5.? ?Editorial Member , ? Chinese Journal of Hematology; ? 　 　

6.? ?Managing Editor, Chinese Journal of Internal Medicine; 　 　

7.? ?Editorial Member, Journal of Experimental Hematology; 　 　

8.? ?N ational awards for Science and technology of China (2009) 　 　

9.? ?Scientific Award in Basic and Clinical Study of Epigenetics in Leukemia ?of Beijing, China (2007) 　 　

10.? ?National Scientific Award in the competition of Medical Multiple Media Teaching Material in China ? (2001). 　 　

11.? ?Chinese Military Medicine Scientific ?Award in Lymphoma Diagnosis and Treatment ? (2000). 　 　

　?　 　 　

D.? Contributions to Science 　 　

1. Epigenetic study on leukemia: T he alteration of epigenetic study can affect gene expression, we devoted to explore the influence on Leukemia in terms of its morbidity and prognosis. In ?2005, I was among the first team to characterized that ? Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia (Nature genetics 2005). ?In 2011, my lab demonstrated that m icroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. ? In the following year, We publish ed ?a paper about m ethylation-mediated repression of microRNA-143 enhanceing MLL-AF4 oncogene expression ?( Oncogene 2011, 2012) . In 2013, I demonstrated ?that Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway (Blood 2013). In 2015, my PhD student Gao XN collaborated with the Hormel Institute, characterized that ? AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation ?( Leukemia 2015). 　 　

2. Molecular Diagnosis of leukemia : ?The precision of genetic diagnosis is critical to personalized medicine, our team is devoted to research on molecular diagnosis in Leukemia, especially the leukemia of AML1-ETO / t(8;21).My group has shown that BCR-ABL/GATA1/miR-138 mini cir cuitry contributes to the leukemogenesis of chronic myeloid leukemia in 2014(Oncogene 2014). ? My lab has also shown that a minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia and ?AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia ?( International journal of cancer 2016 , ?Experimental Hematology 2016). In 2016, my team demonstrated that Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing ( Oncotarget 2016 ) . 　 　

3. Transplantation immunology : ? Our research achievements about bone marrow transplantation, immunotherapy and its complications. My group has reported that, similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with hematological malignancies(British journal of hematology 2016). Our ? study ? shown ?that, t he Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements ( Medical science monitor 2016). W e ?has published ?a paper about the e fficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission( PloS one 2015) . ?Moreover , ?we comparatively observed that the efficacy and safety of rabbit anti-thymocyte globulin vs rabbit anti-T-lymphocyte globulin in peripheral blood stem cell transplantation from unrelated donors (Leukemia & lymphoma 2015). 　 　

　?　 　 　

E.? Research Support 　 　

Ongoing Research Support 　 　

1) .Significant New Drugs Creation of ?Major Science and Technology Project (SQ2018ZX090202) ???? 　 　

????????????????2018 to 2020 　 　

Li Yu, PI ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 50 00,000 　 　

DNA demethylating agent decitabine ?based therapy for Acute Myeloid Leukemia and ?drug discovery 　 　

of its Molecular Typing products. 　 　

　?　 　 　

2).Chinese National Natural Science Foundation Project (81670162). ????????????????????????? 2017 ? to ? 2020 　 　

L i ?Y u, ? PI ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ￥ ?700,000 　 　

The study of prognostic genes and their clinical application in t(8;21) acute myeloid leukemia through single-cell RNA-sequencing technique. 　 　

　?　 　 　

3).Chinese National Natural Science Foundation Project (81470010). ?????????????????????????2015 to 2018 　 　

Li Yu, PI ?? ????????????????????????????????????????????????????????????????????????????????????????????????????????????? ? ? ??????? ?￥ 8 00,000 　 　

Mechanism of methylation silenced miR148/152 and demethylation specific outcome on t(8;21) acute myeloid leukemia. 　 　

　?　 　 　

4).Major research plan of Chinese National Natural Science Foundation (90919044). 2015 to 2018 　 　

Li Yu, PI ?? ????????????????????????????????????????????????????????????????????????????????????????????????????????????? ?? ? ??????? ￥ 6 00,000 　 　

Mechanism of regulation network of has-miR-193a and AML1-ETO involved in leukemogenesis. 　 　

　?　 　 　

Completed Research Support 　 　

1).Chinese National Natural Science Foundation Project (81170518). ?????????????????????????2012 to 2015 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 570,000 　 　

Mechanism of epigenetics enhanced immunotherapy on leukemia blasts. 　 　

　?　 　 　

2).Chinese Nation Natural Science Foundation Project (30971297). ????????????????????????????2010 to 2012 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 230,000 　 　

Mechanism of adult acute lymphocytic leukemia immune escape. 　 　

　?　 　 　

3). “863” Program Subtopic (2011AA020117). ??????????????????????????????????????????????????????????????2012 to 2014 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 400,000 　 　

Development of new drugs involved in primary mesenchymal stem cell. 　 　

　?　 　 　

4).Health Care Industry Research Subtopic (201202017). ????????????????????????????????????????????2012 to 2014 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 55 0,000 　 　

The study of standardizing diagnosis and optimizing treatment regimens of hematologic malignancies. 　 　

　?　 　 　

5).Peking Science and Technology Council Health Cultivation of Citizens Project Subtopic (Z111107067311070). ???????????????????????????????????????????????????????????????????????????????????????????????????2011 to 2014 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 35 0,000 　 　

Identification and value for directing personalized therapy of novel biomarkers in hematologic malignancies. 　 　

　?　 　 　

6).Military Hospital Clinical and Advanced Technology Project (2010gxjs091). ????????????2010 to 2013 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 40 0,000 　 　

Specific immunotherapy for early relapse of adult acute lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation. 　 　

　?　 　 　

7).Capital Medical Science Development Foundation Project (2007-2040). ?????????????????2008 to 2011 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 25 0,000 　 　

The study of combining HLA haploidentical hematopoietic stem cell transplantation, clearance of T/B cells and infusion of NK cells to treat hematologic malignancies. 　 　

　?　 　 　

8).Chinese Nation Natural Science Foundation Project (30670898). ????????????????????????????2007 to 2009 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 350 ,000 　 　

Mechanism of regulating KIR3DL1 gene through transcription factor AML2 and DNA methylation. 　 　

? 　 　

9).Chinese Nation Natural Science Foundation Project (30572108). ????????????????????????????2006 to 2008 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 25 0,000 　 　

Mechanism and significance of ID4 gene inhibiting tumorous cellular growth. 　 　

? 　 　

11). “973” Project Subtopic (2005CB522408). ??????????????????????????????????????????????????????????????2005 to 2010 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 2 00,000 　 　

Identification and clinical significance of tumorous genes related to DNA methylation abnormality. 　 　

? 　 　

12). Military Medical Technology Project (01J007). ??????????????????????????????????????????????????????2001 to 2003 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 4 00,000 　 　

The identification, clone, and clinical significance of relapsed acute leukemia-related genes. 　 　

　?　 　 　

13).Chinese Nation Natural Science Foundation Project (39970318). ??????????????????????????2000 to 2002 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 2 00,000 　 　

The study of analyzing DNA methylation patterns of leukemia-related genes and demethylation. 　 　

　?　 　 　

14).Chinese Nation Natural Science Foundation Project. ?????????????????????????????????????????????2000 to 2002 　 　

Li Yu, PI ?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????￥ 18 0,000 　 　

The clone, sequencing analysis and biological significance of RP16 gene related to leukemia. 　 　

　?　 　 　

F.? Peer-reviewed publications (*: corresponding author) 　 　

1.? Yu L , Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C: Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia, Nature genetics ?2005, 37:265-274 . 　 　

2.? Gao XN, Yan F, Lin J, Gao L, Lu XL, Wei SC, Shen N, Pang JX, Ning QY, Komeno Y, Deng AL, Xu YH, Shi JL, Li YH, Zhang DE, Nervi C, Liu SJ, Yu L * : AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation, Leukemia ?2015, 29:1730-1740 　 　

3.? Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou L, Li J, Xu C, Zhou M, Jiang M, Zhou J, Caligiuri MA, Nervi C, Bloomfield CD, Marcucci G, Yu L* : Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway, Blood ?2013, 121:499-509 　 　

4.? Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, Dou L, Gao X, Luo X, Jing Y, Chim CS, Zheng X, ? Yu L * : BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia, Oncogene 2014, 33:44-54 　 　

5.? Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, Kang HY, Yan GT, Wang LL, ? Yu L * : MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia, Oncogene 2011, 30:3416-3428 　 　

6.? Dou L, Zheng D, Li J, Li Y, Gao L, Wang L, Yu L * : Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression, Oncogene 2012, 31:507-517 　 　

7.? Fu L,?Shi J,?Liu A,?Zhou L,?Jiang M,?Fu H,?Xu K,?Li D,?Deng A,?Zhang Q,?Pang Y,?Guo Y,?Hu K,?Zhou J,?Wang Y,?Huang W,?Jing Y,Dou L,?Wang L,?Xu K,?Ke X,?Nervi C,?Li Y, ?Yu L *: A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia, International journal of cancer 2016 　 　

8.? Li H, Li F, Gao C, Huang W, Bo J, Dou L, Wang L, Jing Y, Wang L, Li W, Yu L * , Liu D: Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies, ?British journal of haematology ?2016 　 　

9.? Wang B, Liu Y, Hou G, Wang L, Lv N, Xu Y, Wang X, Xuan Z, Jing Y, Li H, Jin X, Deng A, Gao X, Dou L, Liang J, Chen C, Li Y, Yu L * : Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing, Oncotarget 2016, 7:32065-32078 ? 　 　

10.? Jing Y, Jin X, Wang L, Dou L, Wang Q, Yao Y, Lian S, Zhou J, Zhu H, Yao Z, Gao L, Li Y, Bai X, Fang M, Yu L * : Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia, Oncotarget ?2016 　 　

11.? Zhou L,?Wang Q,?Chen X,?Fu L,?Zhang X,?Wang L,?Deng A,?L i ?D,?Liu J,?Lv N,?Wang L,?Li Y,?Liu D,? Yu L *,?Dou L: AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia, Experimental Hematology ?2016 　 　

12.? Gong D, Li W, Hu LD, Shen JL, Fang MY, Yang QM, Wang HX, Ke XY, Chen HR, Wang Z, Liu H, Liu F, Ma YG, Wang JW, Li HH, Wang QS, Jing Y, Gao XN, Dou LP, Li YH, Luo JM, Yu L * : Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China, Acta haematologica ?2016, 136:201-209 　 　

13.? Liu J, Huang H, ? Yu L , Liu L, Li J, Liu Z, Lu J, Ouyang J, Song Y, Zhou D, Ren H, Ma J, Wang C, Yu L, Zhou J, Wang J, Xiao Y, Huang X: Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China, Tumour biology 2016, 37:7893-7900 　 　

14.? Jing Y, Li J, Yuan L, Zhao X, Wang Q, Yu L , Zhou D, Huang W: Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia, Clinical transplantation ?2016, 30:263-269 　 　

15.? Yang H, Huang S, Zhu CY, Gao L, Zhu HY, Lv N, Jing Y, Yu L * : The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements, Medical science monitor 2016, 22:2315-2323 　 　

16.? Huang S, Jiang MM, Chen GF, Qian K, Gao HH, Guan W, Shi JL, Liu AQ, Liu J, Wang BH, Li YH, Yu L * : Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia, Chinese medical journal 2016, 129:1355-1362 　 　

17.? Du X, Jin J, Cai Z, Chen F, Zhou DB, Yu L , Ke X, Li X, Wu D, Meng F, DeMarco D, Zhang J, Mei J, Hou J: Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program, ?BMC cancer 2016, 16:46 　 　

18.? Zhou DB, Yu L , Du X, Jin J, Cai Z, Chen F, Ke X, Li X, Wu D, Meng F, Ai H, Zhang J, DeMarco D, Chen N, Mei J, Wang J, Hou J: Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment, ?International journal of hematology ?2015, 101:569-577 　 　

19.? Wang BH, Li YH, ? Yu L * : Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia, Chinese medical journal ?2015, 128:2395-2403 　 　

20.? Sun Y, Meng F, Han M, Zhang X, Yu L , Huang H, Wu D, Ren H, Wang C, Shen Z, Ji Y, Huang X: Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study, Biology of blood and marrow transplantation ?2015, 21:1117-1126 　 　

21.? Liu M, Li Y, Zhao X, Zhang Y, Zhai B, Zhang Q, Wang L, Zhao Y, Li H, Wang Q, Gao C, Huang W, ? Yu L * : Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients, ?International journal of clinical and experimental medicine ?2015, 8:11794-11802 　 　

22.? Li MY, Xu YY, Kang HY, Wang XR, Gao L, Cen J, Wang W, Wang N, Li YH, Wang LL, Yu L * : Quantitative Detection of ID4 Gene Aberrant Methylation in the Differentiation of Myelodysplastic Syndrome from Aplastic Anemia, Chinese medical journal 2015, 128:2019-2025 　 　

23.? Li D, Wang L, Zhu H, Dou L, Liu D, Fu L, Ma C, Ma X, Yao Y, Zhou L, Wang Q, Zhao Y, Jing Y, Li Y, Yu L * : Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies, PloS one ?2015, 10:e0132620 　 　

24.? Kang H, Wang X, Gao L, Cen J, Li M, Wang W, Wang N, Li Y, Wang L, Yu L * : Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome, European journal of medical research ?2015, 20:16 　 　

25.? Jinlong S, Lin F, Yonghui L, Li Y * , Weidong W: Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia, PloS one 2015, 10:e0118099 　 　

26.? Huang W, Zhao X, Tian Y, Cao T, Li Y, Liu Z, Jing Y, Wang S, Gao C, Yu L : Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study, Medical oncology (Northwood, London, England) 2015, 32:465 　 　

27.? Huang W, Yu L * , Cao T, Li Y, Liu Z, Li H, Bo J, Zhao Y, Jing Y, Wang S, Zhu H, Dou L, Wang Q, Gao C: The efficacy and safety of rabbit anti-thymocyte globulin vs rabbit anti-T-lymphocyte globulin in peripheral blood stem cell transplantation from unrelated donors, Leukemia & lymphoma 2015, 1-9 　 　

28.? Gao X, Lin J, Gao L, Deng A, Lu X, Li Y, Wang L, ? Yu L * : High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia, PloS one 2015, 10:e0124241 　 　

29.? Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L , Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Zhou D, Ning Z, Lu X: Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma, Annals of oncology 2015, 26:1766-1771 ? 　 　

30.? Wang R, Zhu H, Chen Y, Li C, Li F, Shen Z, Tian J, Yu L , Xu B: Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT, Hematological oncology 2014, 32:126-132 　 　

31.? Wang L, Cram DS, Shen J, Wang X, Zhang J, Song Z, Xu G, Li N, Fan J, Wang S, Luo Y, Wang J, Yu L , Liu J, Yao Y: Validation of copy number variation sequencing for detecting chromosome imbalances in human preimplantation embryos, Biology of reproduction ?2014, 91:37 　 　

32.? Luo L, Zhang L, Cai B, Li H, Huang W, Jing Y, Zhu H, Zhao Y, Bo J, Wang Q, Han X, Yu L , Gao C: Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience, Annals of transplantation ?2014, 19:6-12 　 　

33.? Liu M, Li Y, Zhang Y, Zhao X, Zhai B, Zhang Q, Wang L, Zhao Y, Li H, Wang Q, Gao C, Huang W, ? Yu L * : Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis, PloS one 2014, 9:e115461 　 　

34.? Li J, Shen KN, Huang WR, Li LH, Chen H, Chen WM, Liu KY, ? Yu L , Zhou DB: Autologous stem cell transplant can overcome poor prognosis in patients with multiple myeloma with extramedullary plasmacytoma, Leukemia & lymphoma 2014, 55:1687-1690 　 　

35.? Jing Y, Chen H, Liu M, Zhou M, Guo Y, Gao C, Wang Q, Li H, Zhao Y, Bo J, Huang W, Zhu H, Zhang Y, ? Yu L * : Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis, PloS one ?2014, 9:e110431 　 　

36.? Gu Z, Cai B, Yuan L, Li H, Huang W, Jing Y, Zhu H, Zhao Y, Bo J, Wang Q, Han X, Yu L , Gao C: Successful treatment of polymorphic post-transplant lymphoproliferative disorder after allo-HSCT with reduction of immunosuppression, International journal of clinical and experimental medicine 2014, 7:1904-1909 　 　

37.? Fu L, Huang W, Jing Y, Jiang M, Zhao Y, Shi J, Huang S, Xue X, Zhang Q, Tang J, Dou L, Wang L, Nervi C, Li Y, ? Yu L * : AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia, The FEBS journal ?2014, 281:1123-1131 　 　

38.? Cao T, Li Y, Wang Q, Li H, Bo J, Zhao Y, Jing Y, Wang S, Zhu H, Dou L, Jia B, Gao C, Yu L , Huang W: Outcomes of peripheral blood stem cell transplantation in patients from human leukocyte antigen matched or mismatched unrelated donors, Chinese medical journal ?2014, 127:2612-2617 　 　

39.? Zhou JH, Yao YS, Wang LX, Wang J, Li YH, Jiang MM, Zhou MH, Gao XN, Li RS, Wang LL, Yu L * : Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo, Chinese medical journal ?2013, 126:4552-4556 　 　

40.? Zhou J, Li Y, Yao Y, Wang L, Gao L, Gao X, Luo X, Li J, Jiang M, Zhou M, Yu L * : The cancertestis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo, Molecular medicine reports 2013, 8:1549-1555 　 　

41.? Zhang CY, Wang SH, Huang WR, Guo GH, Zhang ZH, Mou WJ, Yu L * , Tian YP: A novel differential predict model based on matrix-assisted laser ionization time-of-flight mass spectrometry and serum ferritin for acute graft-versus-host disease, BioMed research international ?2013, 2013:563751 　 　

42.? Yao Y, Zhou J, Wang L, Gao X, Ning Q, Jiang M, Wang J, Yu L * : Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine, PloS one ?2013, 8:e70522 　 　

43.? Yang Y, Wang LL, Wang HX, Guo ZK, Gao XF, Cen J, Li YH, Dou LP, ? Yu L * : The epigenetically-regulated miR-663 targets H-ras in K-562 cells, The FEBS journal ?2013, 280:5109-5117 　 　

44.? Wang LX, Mei ZY, Zhou JH, Yao YS, Li YH, Xu YH, Li JX, Gao XN, Zhou MH, Jiang MM, Gao L, Ding Y, Lu XC, Shi JL, Luo XF, Wang J, Wang LL, Qu C, Bai XF, Yu L * : Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses, PloS one ?2013, 8:e62924 　 　

45.? Sun JZ, Gao L, Wang W, Du N, Yang J, Wan L, Liu F, Wang LL, Yu L * : Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic T lymphocyte function in a mouse mammary model, BioMed research international 2013, 2013:196894 　 　

46.? Liu M, Liu J, Liu L, Yu L , Shi B, Ye L, Zhang Y, Chen H: A case report of acute myeloid leukemia after liver transplantation, Acta haematologica ?2013, 129:225-228 　 　

47.? Liu F, Gao L, Jing Y, Xu YY, Ding Y, Zhou MH, Ma C, Li MY, Sun JZ, Wang LL, Yu L * : Detection and clinical significance of gene rearrangements in Chinese patients with adult acute lymphoblastic leukemia, Leukemia & lymphoma ?2013, 54:1521-1526 　 　

48.? Li Y, Gao L, Ding Y, Xu Y, Zhou M, Huang W, Jing Y, Li H, Wang L, Yu L * : Establishment and application of real-time quantitative PCR for diagnosing invasive aspergillosis via the blood in hematological patients: targeting a specific sequence of Aspergillus 28S-ITS2, BMC infectious diseases ?2013, 13:255 　 　

49.? Jing Y, Li H, Zhao Y, Bo J, Wang S, Wang Q, Huang W, Gao C, Yu L * : Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission, Bone marrow transplantation ?2013, 48:383-389 　 　

50.? Guan L, Gao L, Wang L, Li M, Yin Y, ? Yu L , Gao C: The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients, PloS one 2013, 8:e83334 ? 　 　

51.? Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, Li YH, Wang LL, ?Yu L * : A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells, PloS one ?2013, 8:e55481 　 　

52.? Dou L, Li J, Zheng D, Li Y, Gao X, Xu C, Gao L, Wang L, Yu L * : MicroRNA-205 downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic leukemia, Oncotargets and therapy ?2013, 6:1153-1160 　 　

53.? Dou L, Li J, Zheng D, Li Y, Gao X, Xu C, Gao L, Wang L, Yu L * : MicroRNA-142-3p inhibits cell proliferation in human acute lymphoblastic leukemia by targeting the MLL-AF4 oncogene, Molecular biology reports ?2013, 40:6811-6819 　 　

54.? Cen J, Shen J, Wang X, Kang H, Wang L, Sun L, Li Y, ?Yu L * : Association between lymphoma prognosis and aberrant methylation of ID4 and ZO-1 in bone marrow and paraffin-embedded lymphoma tissues of treatment-naive patients, ?Oncology reports ?2013, 30:455-461 　 　

55.? Zhou MH, Gao L, Jing Y, Xu YY, Ding Y, Wang N, Wang W, Li MY, Han XP, Sun JZ, Wang LL, Yu L * : Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia, Annals of hematology 2012, 91:1235-1243 　 　

56.? Yang Y, Wang LL, Li YH, Gao XN, Liu Y, Yu L * : Effect of CpG island methylation on microRNA expression in the k-562 cell line, Biochemical genetics ?2012, 50:122-134 　 　

57.? Wang LX, Talebian F, Liu JQ, Khattabi M, ? Yu L * , Bai XF: IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours, Scandinavian journal of immunology ?2012, 75:273-281 　 　

58.? Huang W, Li J, Li H, Kang W, Bo J, Zhao Y, Gao C, Zhou D, ?Yu L * : High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy, Leukemia & lymphoma 2012, 53:2507-2510 　 　

59.? Huang W, Li H, Gao C, Bo J, Wang Q, Zhao Y, Jing Y, Wang S, Zhu H, Dou L, Wang L, ? Yu L * : Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies, Transfusion ?2012, 52:1354-1362 　 　

60.? Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L , Zucknick M, Mertens D, Buhler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Dohner H, Heerema NA, Marcucci G, Plass C, Byrd JC: Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia, ?Journal of clinical oncology ?2012, 30:2483-2491 　 　

61.? Zhou Y, Huang W, Li H, Yu L * : Unmanipulated haploidentical peripheral blood stem cell transplantation for precursor T-cell lymphoblastic lymphoma relapsed after autologous PBSCT, Journal of pediatric hematology/oncology ?2011, 33:224-226 　 　

62.? Yuan L, Sun L, Bo J, Zhou Y, Li HH, Yu L , Gao CJ: Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine, Annals of transplantation ?2011, 16:135-138 　 　

63.? Wang W, Gao L, Wang X, Kang H, Li Y, Wang L, Yu L * : Modulation of the poliovirus receptor expression in malignant lymphocytes by epigenetic alterations, Journal of immunotherapy ?(Hagerstown, Md : 1997) 2011, 34:353-361 　 　

64.? Li M, Gao C, Li H, Wang Z, Cao Y, Huang W, Li X, Wang S, Yu L , Da W: Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/T-cell lymphoma, Medical oncology (Northwood, London, England) 2011, 28:840-845 　 　

65.? Gao XN, Lin J, Gao L, Li YH, Wang LL, Yu L * : MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia, Leukemia research 2011, 35:1226-1232 　 　

66.? Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, ? Yu L : Epigenetic inactivation of the hsa-miR-203 in haematological malignancies, Journal of cellular and molecular medicine 2011, 15:2760-2767 　 　

67.? Wong KY, Yu L , Chim CS: DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family, Epigenomics ?2011, 3:83-92 　 　

68.? Chen SS, Claus R, Lucas DM, Yu L , Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F, Plass C, Byrd JC: Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL, Blood ?2011, 117:862-871 　 　

69.? Wang L, Liu JQ, Talebian F, El-Omrani HY, Khattabi M, ? Yu L , Bai XF: Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy, European journal of immunology ?2010, 40:2569-2579 　 　

70.? Han W, Chen M, Li M, Wu Z, Zhao Y, Wang Y, Wang L, Yu L , Fu X: Acclimatized induction reveals the multipotency of adult human undifferentiated keratinocytes, Cellular reprogramming ?2010, 12:283-294 　 　

71.? Chen SL, Jiang B, Qiu LG, ? Yu L , Zhong YP, Gao W: Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China, Anatomical record (Hoboken, NJ : 2007) 2010, 293:1679-1684 　 　

72.? Gao XN, Lin J, Wang LL, Yu L * : Demethylating treatment suppresses natural killer cell cytolytic activity, Molecular immunology ?2009, 46:2064-2070 　 　

73.? Yu J, Ershler M, Yu L , Wei M, Hackanson B, Yokohama A, Mitsui T, Liu C, Mao H, Liu S, Liu Z, Trotta R, Liu CG, Liu X, Huang K, Visser J, Marcucci G, Plass C, Belyavsky AV, Caligiuri MA: TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia, Blood ?2009, 113:5558-5567 　 　

74.? Han W, Wu Z, Zhao Y, Meng Y, Si Y, Yang J, Fu X, Yu L : FHL2 interacts with and acts as a functional repressor of Id2 in human neuroblastoma cells, Nucleic acids research ?2009, 37:3996-4009 ? 　 　

75.? Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L , Liu C, Bloomfield CD, Marcucci G, Plass C, Caligiuri MA: DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication, Blood 2008, 112:2013-2016 ? 　 　

76.? Zhu H, Zhao D, Han X, Sun J, Da W, Yu L , Gao C: Identification of a new HLA-Cw*07 allele, HLA-Cw*0743, from a Chinese hematopoietic stem cell donor, International journal of hematology 2008, 88:321-323 　 　

77.? Gao XN, ? Yu L : E2F1 contributes to the transcriptional activation of the KIR3DL1 gene, Biochemical and biophysical research communications ?2008, 370:399-403 　 　

78.? Dou LP, Zheng de H, Wang C, Liu JH, Sun JF, Jin HJ, Gao CJ, ? Yu L , Da WM: The diversity of KIR gene in Chinese Northern Han population and the impact of donor KIR and patient HLA genotypes on outcome following HLA-identical sibling allogeneic hematopoietic stem cell transplantation for hematological malignancy in Chinese people, ?International journal of hematology ?2008, 87:422-433 　 　

79.? Allegrucci C, Wu YZ, Thurston A, Denning CN, Priddle H, Mummery CL, Ward-van Oostwaard D, Andrews PW, Stojkovic M, Smith N, Parkin T, Jones ME, Warren G, Yu L , Brena RM, Plass C, Young LE: Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome, Human molecular genetics ?2007, 16:1253-1268 　 　

80.? Smiraglia DJ, Kazhiyur-Mannar R, Oakes CC, Wu YZ, Liang P, Ansari T, Su J, Rush LJ, Smith LT, Yu L , Liu C, Dai Z, Chen SS, Wang SH, Costello J, Ioshikhes I, Dawson DW, Hong JS, Teitell MA, Szafranek A, Camoriano M, Song F, Elliott R, Held W, Trasler JM, Plass C, Wenger R: Restriction landmark genomic scanning (RLGS) spot identification by second generation virtual RLGS in multiple genomes with multiple enzyme combinations, ?BMC genomics 2007, 8:446 　 　

81.? Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, Guimond M, Strout MP, Feng L, Nakamura T, Yu L , Rush LJ, Weinstein M, Leone G, Wu L, Ferketich A, Whitman SP, Marcucci G, Caligiuri MA: Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations, The Journal of clinical investigation ?2006, 116:2707-2716 ? 　 　

82.? Rosenbauer F, Owens BM, Yu L , Tumang JR, Steidl U, Kutok JL, Clayton LK, Wagner K, Scheller M, Iwasaki H, Liu C, Hackanson B, Akashi K, Leutz A, Rothstein TL, Plass C, Tenen DG: Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1, Nature genetics ?2006, 38:27-37 　 　

83.? Zhao YL, Han WD, Li Q, Mu YM, Lu XC, Yu L , Song HJ, Li X, Lu JM, Pan CY: Mechanism of transcriptional regulation of LRP16 gene expression by 17-beta estradiol in MCF-7 human breast cancer cells, Journal of molecular endocrinology 2005, 34:77-89 　 　

84.? Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, Yu J, Becknell B, Yu L , Liu C, Vukosavljevic T, Whitman SP, Chang KS, Byrd JC, Perrotti D, Plass C, Marcucci G: Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia, Cancer research ?2005, 65:1277-1284 　 　

85.? Whitman SP, Liu S, Vukosavljevic T, Rush LJ, ? Yu L , Liu C, Klisovic MI, Maharry K, Guimond M, Strout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD, Marcucci G, Caligiuri MA: The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy, Blood 2005, 106:345-352 　 　

86.? Yu L , Liu C, Bennett K, Wu YZ, Dai Z, Vandeusen J, Opavsky R, Raval A, Trikha P, Rodriguez B, Becknell B, Mao C, Lee S, Davuluri RV, Leone G, Van den Veyver IB, Caligiuri MA, Plass C: A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies, Genomics ?2004, 84:647-660 　 　

87.? Han WD, Mu YM, Lu XC, Xu ZM, Li XJ, Yu L , Song HJ, Li M, Lu JM, Zhao YL, Pan CY: Up-regulation of LRP16 mRNA by 17beta-estradiol through activation of estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of human breast cancer MCF-7 cell proliferation: a preliminary report, ?Endocrine-related cancer ?2003, 10:217-224 　 　

88.? Dai Z, Weichenhan D, Wu YZ, Hall JL, Rush LJ, Smith LT, Raval A, Yu L , Kroll D, Muehlisch J, Fruhwald MC, de Jong P, Catanese J, Davuluri RV, Smiraglia DJ, Plass C: An AscI boundary library for the studies of genetic and epigenetic alterations in CpG islands, Genome research 2002, 12:1591-1598 ? 　 　

89.? Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Fruhwald M, Costello JF, Held WA, Yu L , Krahe R, Kolitz JE, Bloomfield CD, Caligiuri MA, Plass C: Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci, ?Blood 2001, 97:3226-3233 ? 　 　

90.? Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, ? Yu L , Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns, Nature genetics 2000, 24:132-138 　 　

91.? Plass C, Yu F, Yu L , Strout MP, El-Rifai W, Elonen E, Knuutila S, Marcucci G, Young DC, Held WA, Bloomfield CD, Caligiuri MA: Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene, ?Oncogene 1999, 18:3159-3165 ? 　 　

92.? Plass C, Weichenhan D, Catanese J, Costello JF, Yu F, Yu L , Smiraglia D, Cavenee WK, Caligiuri MA, deJong P, Held WA: An arrayed human not I-EcoRV boundary library as a tool for RLGS spot analysis, DNA research ?1997, 4:253-255